Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Influence of Zirconia-Coated Bioactive Glass on Gingival Fibroblast Behavior.

Barros SAL, Soares DG, Leite ML, Basso FG, Costa CAS, Adabo GL.

Braz Dent J. 2019 Jul 22;30(4):333-341. doi: 10.1590/0103-6440201902417.

2.

Safety evaluation of 2'-deoxy-2'-fluoro nucleotides in GalNAc-siRNA conjugates.

Janas MM, Zlatev I, Liu J, Jiang Y, Barros SA, Sutherland JE, Davis WP, Liu J, Brown CR, Liu X, Schlegel MK, Blair L, Zhang X, Das B, Tran C, Aluri K, Li J, Agarwal S, Indrakanti R, Charisse K, Nair J, Matsuda S, Rajeev KG, Zimmermann T, Sepp-Lorenzino L, Xu Y, Akinc A, Fitzgerald K, Vaishnaw AK, Smith PF, Manoharan M, Jadhav V, Wu JT, Maier MA.

Nucleic Acids Res. 2019 Apr 23;47(7):3306-3320. doi: 10.1093/nar/gkz140.

3.

Impact of Oligonucleotide Structure, Chemistry, and Delivery Method on In Vitro Cytotoxicity.

Janas MM, Jiang Y, Schlegel MK, Waldron S, Kuchimanchi S, Barros SA.

Nucleic Acid Ther. 2017 Feb;27(1):11-22. doi: 10.1089/nat.2016.0639. Epub 2016 Dec 6.

PMID:
27923110
4.

Exposure to siRNA-GalNAc Conjugates in Systems of the Standard Test Battery for Genotoxicity.

Janas MM, Jiang Y, Duncan RG, Hayes AN, Liu J, Kasperkovitz PV, Placke ME, Barros SA.

Nucleic Acid Ther. 2016 Dec;26(6):363-371. Epub 2016 Jul 7.

PMID:
27387336
5.

Modulation of the E. coli rpoH Temperature Sensor with Triptycene-Based Small Molecules.

Barros SA, Yoon I, Chenoweth DM.

Angew Chem Int Ed Engl. 2016 Jul 11;55(29):8258-61. doi: 10.1002/anie.201601626. Epub 2016 May 30.

6.

Bridgehead-Substituted Triptycenes for Discovery of Nucleic Acid Junction Binders.

Barros SA, Yoon I, Suh SE, Chenoweth DM.

Org Lett. 2016 May 20;18(10):2423-6. doi: 10.1021/acs.orglett.6b00945. Epub 2016 May 12.

7.

OSWG Recommendations for Genotoxicity Testing of Novel Oligonucleotide-Based Therapeutics.

Berman CL, Barros SA, Galloway SM, Kasper P, Oleson FB, Priestley CC, Sweder KS, Schlosser MJ, Sobol Z.

Nucleic Acid Ther. 2016 Apr;26(2):73-85. doi: 10.1089/nat.2015.0534. Epub 2016 Mar 15. Review.

PMID:
26978711
8.

Synthesis of 9-Substituted Triptycene Building Blocks for Solid-Phase Diversification and Nucleic Acid Junction Targeting.

Yoon I, Suh SE, Barros SA, Chenoweth DM.

Org Lett. 2016 Mar 4;18(5):1096-9. doi: 10.1021/acs.orglett.6b00169. Epub 2016 Feb 17.

9.
10.

Triptycene-based small molecules modulate (CAG)·(CTG) repeat junctions.

Barros SA, Chenoweth DM.

Chem Sci. 2015 Aug 14;6(8):4752-4755. Epub 2015 Jun 10.

11.

Shielding of Lipid Nanoparticles for siRNA Delivery: Impact on Physicochemical Properties, Cytokine Induction, and Efficacy.

Kumar V, Qin J, Jiang Y, Duncan RG, Brigham B, Fishman S, Nair JK, Akinc A, Barros SA, Kasperkovitz PV.

Mol Ther Nucleic Acids. 2014 Nov 18;3:e210. doi: 10.1038/mtna.2014.61.

12.

Recognition of nucleic acid junctions using triptycene-based molecules.

Barros SA, Chenoweth DM.

Angew Chem Int Ed Engl. 2014 Dec 8;53(50):13746-50. doi: 10.1002/anie.201407061. Epub 2014 Sep 24.

13.

Lipopeptide nanoparticles for potent and selective siRNA delivery in rodents and nonhuman primates.

Dong Y, Love KT, Dorkin JR, Sirirungruang S, Zhang Y, Chen D, Bogorad RL, Yin H, Chen Y, Vegas AJ, Alabi CA, Sahay G, Olejnik KT, Wang W, Schroeder A, Lytton-Jean AK, Siegwart DJ, Akinc A, Barnes C, Barros SA, Carioto M, Fitzgerald K, Hettinger J, Kumar V, Novobrantseva TI, Qin J, Querbes W, Koteliansky V, Langer R, Anderson DG.

Proc Natl Acad Sci U S A. 2014 Mar 18;111(11):3955-60. doi: 10.1073/pnas.1322937111. Epub 2014 Feb 10. Erratum in: Proc Natl Acad Sci U S A. 2014 Apr 15;111(15):5753.

14.

Safety profile of RNAi nanomedicines.

Barros SA, Gollob JA.

Adv Drug Deliv Rev. 2012 Dec;64(15):1730-7. doi: 10.1016/j.addr.2012.06.007. Epub 2012 Jun 22. Review.

PMID:
22732527
15.

Rational design of cationic lipids for siRNA delivery.

Semple SC, Akinc A, Chen J, Sandhu AP, Mui BL, Cho CK, Sah DW, Stebbing D, Crosley EJ, Yaworski E, Hafez IM, Dorkin JR, Qin J, Lam K, Rajeev KG, Wong KF, Jeffs LB, Nechev L, Eisenhardt ML, Jayaraman M, Kazem M, Maier MA, Srinivasulu M, Weinstein MJ, Chen Q, Alvarez R, Barros SA, De S, Klimuk SK, Borland T, Kosovrasti V, Cantley WL, Tam YK, Manoharan M, Ciufolini MA, Tracy MA, de Fougerolles A, MacLachlan I, Cullis PR, Madden TD, Hope MJ.

Nat Biotechnol. 2010 Feb;28(2):172-6. doi: 10.1038/nbt.1602. Epub 2010 Jan 17.

PMID:
20081866
16.

Activation of protein kinase Czeta increases OAT1 (SLC22A6)- and OAT3 (SLC22A8)-mediated transport.

Barros SA, Srimaroeng C, Perry JL, Walden R, Dembla-Rajpal N, Sweet DH, Pritchard JB.

J Biol Chem. 2009 Jan 30;284(5):2672-9. doi: 10.1074/jbc.M808078200. Epub 2008 Nov 21.

17.

Predictive toxicogenomics in preclinical discovery.

Barros SA, Martin RB.

Methods Mol Biol. 2008;460:89-112. doi: 10.1007/978-1-60327-048-9_5.

PMID:
18449484
18.

The importance of applying toxicogenomics to increase the efficiency of drug discovery.

Barros SA.

Pharmacogenomics. 2005 Sep;6(6):547-50. No abstract available.

19.

Bowel function following insertion of self-expanding metallic stents for palliation of colorectal cancer.

Davies RJ, D'Sa IB, Lucarotti ME, Fowler AL, Tottle A, Birch P, Cook TA.

Colorectal Dis. 2005 May;7(3):251-3.

PMID:
15859963
20.

Molecular structure and characterization of a novel murine ABC transporter, Abca13.

Barros SA, Tennant RW, Cannon RE.

Gene. 2003 Mar 27;307:191-200.

PMID:
12706902
21.

[Various aspects of biliary dyskinesia].

de BARROS SA.

Arq Cir Clin Exp. 1950 Nov-Dec;13(6):499-503. Undetermined Language. No abstract available.

PMID:
24540896

Supplemental Content

Loading ...
Support Center